ArticleMicrosystems & nanoengineering2026
Integrated precise temperature regulation and electrophysiology sensing system for nanoplasmonic photothermal cardiac bradyarrhythmia therapy.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bradyarrhythmia is a potentially life-threatening disease. Current pharmacological and surgical treatments are limited by side effects and invasiveness, with an urgent need for safer and noninvasive therapeutic strategies. In this study, we develop a multifunctional regulating-sensing platform that integrates precise temperature regulation with simultaneous electrophysiological detection. This platform employs gold nanorods (Au NRs) as nanoplasmonic photothermal effect carriers in combination with integrated serpentine-shaped resistance temperature sensors (RTSs) and a microelectrode array (MEA) device. Under near-infrared (NIR) irradiation, the RTS achieves precise regulation of the therapeutic temperature during nanoplasmonic photothermal therapy (NPT), while the MEA is utilized for dynamic monitoring of electrophysiological signals. The optimization of the RTS structural parameters enhances temperature response sensitivity. Precise modulation of NPT temperature enables restoration of the bradyarrhythmia cardiomyocytes to a normal rhythm, which can be sustained for up to 380 min. Compared with traditional thermal imaging strategy, the RTS-based strategy offers superior temperature resolution, shorter response time, and greater system integration potential, which significantly improves the safety and accuracy of the treatment. This integrated regulating-sensing platform provides an effective pathway for the precise treatment of bradyarrhythmia and holds significant implications in the field of clinical cardiology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.